Eli Lilly

Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks

Yuvraj — Tue, 21 Apr 2026 05:47:56 +0000

Eli Lilly and Company is in advanced discussions to acquire Kelonia Therapeutics for more than $2 billion, according to a report by The Wall Street Journal. The report, citing people familiar with the matter, indicates that a deal could be finalized as early as Monday and may include additional payments tied to the achievement of […]

The post Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks first appeared on World Pharma Today.

Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal

Yuvraj — Fri, 03 Apr 2026 08:47:22 +0000

Eli Lilly & Co. is set to acquire Centessa Pharmaceuticals Plc in a transaction worth up to $7.8 billion, underscoring its push to broaden its drug development pipeline. The Centessa Pharmaceuticals deal highlights the company’s effort to expand into therapeutic areas beyond its current core focus, particularly within neuroscience. Under the terms announced Tuesday, Lilly will […]

The post Eli Lilly to Acquire Centessa Pharmaceuticals in $7.8B Deal first appeared on World Pharma Today.

Lilly, Insilico Sign $2.75B AI Drug Discovery Collaboration

Yuvraj — Mon, 30 Mar 2026 12:04:56 +0000

Eli Lilly has expanded its engagement with Insilico Medicine, formalising a new AI drug discovery collaboration valued at up to $2.75 billion, further extending a relationship that began with an AI software licensing agreement in 2023. The latest agreement follows a $100 million partnership signed in November 2025 and is designed to broaden the company’s […]

The post Lilly, Insilico Sign $2.75B AI Drug Discovery Collaboration first appeared on World Pharma Today.

Lilly Launches New AI Supercomputer for Drug Development

Yuvraj — Mon, 02 Mar 2026 13:45:04 +0000

Eli Lilly has launched what it describes as the most powerful AI factory wholly owned and operated by a pharmaceutical company, marking a significant expansion of advanced computing infrastructure in life sciences. The system, named LillyPod, was inaugurated in Indianapolis and is built as the world’s first NVIDIA DGX SuperPOD with DGX B300 systems, powered […]

The post Lilly Launches New AI Supercomputer for Drug Development first appeared on World Pharma Today.

Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data

Yuvraj — Thu, 19 Feb 2026 09:29:18 +0000

Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients living with both psoriasis and obesity in a late-stage study. The psoriasis trial enrolled 274 patients and evaluated whether the addition of Zepbound could enhance both dermatologic and weight-loss outcomes. After […]

The post Lilly Zepbound-Taltz Combo Gains Ground with Phase 3b Data first appeared on World Pharma Today.

Weight-Loss Pills Mark a Turning Point for Pharma Industry

Yuvraj — Mon, 16 Feb 2026 11:58:02 +0000

The global pharmaceutical industry is entering a pivotal phase in obesity therapeutics as companies accelerate the transition from injectable GLP-1 drugs to oral weight-loss treatments, a shift expected to significantly expand patient access, alter reimbursement dynamics, and intensify competitive pressures in one of the fastest-growing drug categories. The commercial success of GLP-1 receptor agonists such […]

The post Weight-Loss Pills Mark a Turning Point for Pharma Industry first appeared on World Pharma Today.

Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies

Yuvraj — Wed, 11 Feb 2026 09:50:59 +0000

Eli Lilly has agreed to acquire in vivo CAR-T developer Orna Therapeutics in a deal worth up to $2.4 billion, marking another rapid move to strengthen its research pipeline. The transaction positions Lilly buys Orna for $2.4bn as a strategic step into next-generation cell therapies delivered directly inside the body. Watertown, Massachusetts-based Orna is developing […]

The post Lilly Buys Orna for $2.4bn to Advance In Vivo Therapies first appeared on World Pharma Today.

Innovent-Lilly Partnership Expands Global Drug Development

Yuvraj — Tue, 10 Feb 2026 12:53:48 +0000

Innovent Biologics has announced a strategic Innovent-Lilly partnership with Eli Lilly and Company to advance the global development of new medicines in oncology and immunology. The agreement represents the seventh partnership between the two companies and introduces a new model to accelerate worldwide pipeline development. Under the Innovent-Lilly partnership, Innovent will lead research and development […]

The post Innovent-Lilly Partnership Expands Global Drug Development first appeared on World Pharma Today.

Seamless Therapeutics and Eli Lilly Hearing Loss Collaboration

Yuvraj — Wed, 04 Feb 2026 09:04:25 +0000

Seamless Therapeutics has entered a global research collaboration and licensing agreement with Eli Lilly and Company under the Seamless Therapeutics Eli Lilly hearing loss collaboration, focused on developing programmable recombinase-based genetic medicines for hearing loss. The collaboration will unite Seamless Therapeutics’ recombinase platform with Lilly’s expertise in hearing-loss diseases. The platform aims to facilitate the […]

The post Seamless Therapeutics and Eli Lilly Hearing Loss Collaboration first appeared on World Pharma Today.

Revvity and Lilly Expand Lilly TuneLab Access via Signals

Yuvraj — Tue, 13 Jan 2026 13:31:09 +0000

Revvity, Inc. announced a collaboration with Eli Lilly and Company to broaden access to Lilly TuneLab by bringing the platform to the Revvity Signals ecosystem. The collaboration builds on Revvity’s recently launched Signals Xynthetica offering and aims to accelerate AI-enabled drug discovery through a federated learning approach. Lilly TuneLab was designed to provide wider Lilly […]

The post Revvity and Lilly Expand Lilly TuneLab Access via Signals first appeared on World Pharma Today.